PriceTargets.com logo

Savara - SVRA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.20
  • Forecasted Upside: 84.27%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$4.45 As of 04/25/2024 01:00 AM ET
▲ +0.21 (4.95%)

This chart shows the closing price for SVRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Savara Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SVRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SVRA

Analyst Price Target is $8.20
▲ +84.27% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Savara in the last 3 months. The average price target is $8.20, with a high forecast of $16.00 and a low forecast of $4.00. The average price target represents a 84.27% upside from the last price of $4.45.

This chart shows the closing price for SVRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Savara. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$8.00Low
3/4/2024Piper SandlerBoost TargetOverweight ➝ Overweight$7.00 ➝ $16.00Low
2/15/2024JMP SecuritiesInitiated CoverageOutperform$8.00Low
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
11/7/2023GuggenheimInitiated CoverageBuy$7.00Low
8/14/2023HC WainwrightBoost TargetBuy ➝ Buy$3.00 ➝ $6.00Low
5/16/2023Jefferies Financial GroupUpgradeHold ➝ Buy$2.00 ➝ $4.00Low
4/4/2023HC WainwrightReiterated RatingBuy$3.00Low
3/31/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$2.00Low
11/14/2022HC WainwrightReiterated RatingBuy$3.00Low
5/14/2021HC WainwrightReiterated RatingBuyLow
3/16/2021Piper SandlerInitiated CoverageOverweight$7.00High
3/15/2021OppenheimerInitiated CoverageOutperform$4.00High
12/15/2020HC WainwrightLower TargetBuy$6.00 ➝ $3.00High
11/23/2020Evercore ISIInitiated CoverageOutperformMedium
3/17/2020HC WainwrightReiterated RatingBuyHigh
12/20/2019HC WainwrightReiterated RatingBuy$6.00High
10/3/2019LADENBURG THALM/SH SHReiterated RatingHold$1.00Low
8/12/2019Evercore ISISet TargetBuy$17.00Medium
6/13/2019HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $6.00N/A
6/13/2019LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$21.00 ➝ $3.00N/A
6/13/2019JMP SecuritiesDowngradeOutperform ➝ Market Perform$2.60N/A
5/14/2019Roth CapitalSet TargetHold$10.00High
5/10/2019LADENBURG THALM/SH SHReiterated RatingBuyHigh
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Savara logo
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Read More

Today's Range

Now: $4.45
Low: $4.06
High: $4.46

50 Day Range

MA: $4.93
Low: $4.24
High: $5.59

52 Week Range

Now: $4.45
Low: $1.78
High: $5.70

Volume

1,253,320 shs

Average Volume

852,109 shs

Market Capitalization

$614.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Savara?

The following Wall Street research analysts have issued reports on Savara in the last twelve months: Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, and Piper Sandler.
View the latest analyst ratings for SVRA.

What is the current price target for Savara?

5 Wall Street analysts have set twelve-month price targets for Savara in the last year. Their average twelve-month price target is $8.20, suggesting a possible upside of 84.3%. Piper Sandler has the highest price target set, predicting SVRA will reach $16.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $4.00 for Savara in the next year.
View the latest price targets for SVRA.

What is the current consensus analyst rating for Savara?

Savara currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SVRA will outperform the market and that investors should add to their positions of Savara.
View the latest ratings for SVRA.

What other companies compete with Savara?

Other companies that are similar to Savara include Aerovate Therapeutics, Praxis Precision Medicines, Pharming Group, Disc Medicine and Cogent Biosciences. Learn More about companies similar to Savara.

How do I contact Savara's investor relations team?

Savara's physical mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The company's listed phone number is 512-614-1848 and its investor relations email address is [email protected]. The official website for Savara is www.savarapharma.com. Learn More about contacing Savara investor relations.